세계의 임상시험용 이미징 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)

The global market for Clinical Trial Imaging was estimated to be worth US$ 1579 million in 2024 and is forecast to a readjusted size of US$ 2501 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.

Clinical trial imaging refers to the process of using imaging technology (such as X-ray, CT, MRI, etc.) to observe and analyze the subjects in vivo during clinical trials. It plays an irreplaceable role in evaluating the efficacy, safety and side effects of new drugs, treatments or medical devices. Through imaging technology, researchers can intuitively observe the distribution, metabolism and mechanism of action of drugs in the body, providing a scientific basis for the clinical application of drugs.

The core manufacturers of clinical trial imaging in the world include Clario, ICON, McLaren, Calyx and BioTelemetry. The top five companies hold about 60% of the shares. North America is the largest market, with a share of about 33%, followed by Europe and Asia Pacific, each with a share of about 27%. In terms of product type, central imaging services are the largest market segment, with a share of about 70%. In terms of application, the largest application is pharmaceutical companies, followed by biotechnology companies.

In the process of clinical trial imaging, ethical principles and regulatory requirements must be strictly followed. Researchers need to ensure that the informed consent rights of subjects are fully guaranteed and that scientific principles and ethical standards are strictly followed during the trial. At the same time, regulatory agencies also need to strengthen the supervision of clinical trial imaging to ensure the reliability and validity of trial results.

Clinical trial imaging plays an important role in different stages of drug development. For example, in Phase I clinical trials, imaging technology can be used to observe the pharmacokinetic characteristics of drugs in the human body; in Phase II/III clinical trials, the efficacy and safety of drugs can be evaluated.

For new medical devices, clinical trial imaging can be used to evaluate their performance, safety and clinical application value. By comparing the effects of using new equipment with existing equipment, strong support can be provided for the promotion and application of medical equipment.

In clinical trials, imaging technology can also be used for early diagnosis of diseases, disease monitoring and evaluation of treatment effects. For example, in tumor treatment, regular imaging examinations can be used to observe the size, morphology and changes of tumors, so as to adjust the treatment plan in time.

With the continuous advancement of medical technology and the increasing demand for clinical trials, the clinical trial imaging market will usher in a broader development prospect. In the future, this field will pay more attention to the development of technological innovation and personalized services to meet the needs of different clinical trials.

The driving factors of the clinical trial imaging market mainly include the following:

Technological progress: innovation drives core growth

High-precision and multimodal imaging technology

Breakthroughs in technologies such as MRI, CT, and PET: High-resolution imaging technology (such as 3T MRI and ultra-low-dose CT) provides more accurate anatomical and functional information, which helps early diagnosis of diseases and efficacy evaluation.

Multimodal fusion: The fusion technology of CT and MRI, PET and CT, combined with anatomical and metabolic information, significantly improves diagnostic sensitivity, such as in tumor staging.

Artificial Intelligence and Automation

AI-assisted analysis: Deep learning algorithms can automatically detect lesions (such as lung nodules and breast calcifications), reduce human errors, and improve diagnostic efficiency.

Process Automation: AI optimizes scanning protocols and automatically generates reports, shortens clinical trial cycles, and reduces costs.

Portable and Real-time Imaging

Portable ultrasound equipment: Suitable for bedside examinations and remote areas, expanding the coverage of clinical trials.

Real-time imaging technology: such as ultrasound elastic imaging, dynamically monitors changes in tissue hardness, and provides instant feedback for diseases such as liver fibrosis.

Policy support: Create a favorable development environment

Improvement of regulatory framework

FDA, NMPA and other agencies: Ensure the safety and effectiveness of equipment through strict approval processes, such as requiring that Class III medical imaging equipment must pass clinical trials before registration.

International Standard Coordination: Promote imaging protocols and data standardization (such as DICOM format) and promote multi-center trial data sharing.

Funding and Incentives

Government research funding: For example, China's "14th Five-Year Plan" special support for medical imaging technology to accelerate technology transformation.

Tax incentives and subsidies: Encourage corporate R&D and innovation, such as providing financial subsidies for localization projects of high-end imaging equipment.

Growth in medical demand: changes in population and disease structure

Aging and chronic disease burden

High incidence of cancer and neurodegenerative diseases: The global incidence of cancer is rising, driving the demand for early screening and efficacy monitoring.

Demand for precision medicine: Individualized treatment relies on high-precision imaging (such as molecular imaging in tumor targeted therapy).

New drug development and clinical trial expansion

Innovative drug development boom: The number of new drugs under development has surged globally, and the demand for imaging in clinical trials has increased accordingly.

Rare diseases and real-world research: Imaging technology helps small sample size trials and long-term efficacy tracking.

The growth of the clinical trial imaging market is the result of technological innovation, policy dividends, demand upgrades and the evolution of the competitive landscape. In the future, with the deep integration of AI, multimodal imaging and cloud technology, the market will accelerate its development towards intelligence and precision. At the same time, the rise of local companies will reshape the global competitive landscape and inject new vitality into the industry.

This report aims to provide a comprehensive presentation of the global market for Clinical Trial Imaging, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Clinical Trial Imaging by region & country, by Type, and by Application.

The Clinical Trial Imaging market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Clinical Trial Imaging.

Market Segmentation

By Company

• ICON
• ERT
• McLaren
• Bioclinica
• Parexel
• BioTelemetry
• ProScan Imaging
• Imaging Endpoints
• Radiant Sage
• Micron, Inc.
• Intrinsic Imaging
• Median Technologies
• Cardiovascular Imaging Technologies
• Banook Medical
• IXICO
• Tigermed
• Runda Medical
• Konica Minolta
• Keosys

Segment by Type

• In-house Imaging Service
• Central Imaging Service

Segment by Application

• Pharmaceutical Companies
• Biotechnology Companies
• Academic Institutes
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Clinical Trial Imaging company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Clinical Trial Imaging in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Clinical Trial Imaging in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Clinical Trial Imaging Product Introduction
• 1.2 Global Clinical Trial Imaging Market Size Forecast (2020-2031)
• 1.3 Clinical Trial Imaging Market Trends & Drivers
  • 1.3.1 Clinical Trial Imaging Industry Trends
  • 1.3.2 Clinical Trial Imaging Market Drivers & Opportunity
  • 1.3.3 Clinical Trial Imaging Market Challenges
  • 1.3.4 Clinical Trial Imaging Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Clinical Trial Imaging Players Revenue Ranking (2024)
• 2.2 Global Clinical Trial Imaging Revenue by Company (2020-2025)
• 2.3 Key Companies Clinical Trial Imaging Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Clinical Trial Imaging Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Clinical Trial Imaging
• 2.6 Clinical Trial Imaging Market Competitive Analysis
  • 2.6.1 Clinical Trial Imaging Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Clinical Trial Imaging Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Trial Imaging as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 In-house Imaging Service
  • 3.1.2 Central Imaging Service
• 3.2 Global Clinical Trial Imaging Sales Value by Type
  • 3.2.1 Global Clinical Trial Imaging Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Clinical Trial Imaging Sales Value, by Type (2020-2031)
  • 3.2.3 Global Clinical Trial Imaging Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Pharmaceutical Companies
  • 4.1.2 Biotechnology Companies
  • 4.1.3 Academic Institutes
  • 4.1.4 Others
• 4.2 Global Clinical Trial Imaging Sales Value by Application
  • 4.2.1 Global Clinical Trial Imaging Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Clinical Trial Imaging Sales Value, by Application (2020-2031)
  • 4.2.3 Global Clinical Trial Imaging Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Clinical Trial Imaging Sales Value by Region
  • 5.1.1 Global Clinical Trial Imaging Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Clinical Trial Imaging Sales Value by Region (2020-2025)
  • 5.1.3 Global Clinical Trial Imaging Sales Value by Region (2026-2031)
  • 5.1.4 Global Clinical Trial Imaging Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Clinical Trial Imaging Sales Value, 2020-2031
  • 5.2.2 North America Clinical Trial Imaging Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Clinical Trial Imaging Sales Value, 2020-2031
  • 5.3.2 Europe Clinical Trial Imaging Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Clinical Trial Imaging Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Clinical Trial Imaging Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Clinical Trial Imaging Sales Value, 2020-2031
  • 5.5.2 South America Clinical Trial Imaging Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Clinical Trial Imaging Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Clinical Trial Imaging Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Clinical Trial Imaging Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Clinical Trial Imaging Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Clinical Trial Imaging Sales Value, 2020-2031
  • 6.3.2 United States Clinical Trial Imaging Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Clinical Trial Imaging Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Clinical Trial Imaging Sales Value, 2020-2031
  • 6.4.2 Europe Clinical Trial Imaging Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Clinical Trial Imaging Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Clinical Trial Imaging Sales Value, 2020-2031
  • 6.5.2 China Clinical Trial Imaging Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Clinical Trial Imaging Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Clinical Trial Imaging Sales Value, 2020-2031
  • 6.6.2 Japan Clinical Trial Imaging Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Clinical Trial Imaging Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Clinical Trial Imaging Sales Value, 2020-2031
  • 6.7.2 South Korea Clinical Trial Imaging Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Clinical Trial Imaging Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Clinical Trial Imaging Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Clinical Trial Imaging Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Clinical Trial Imaging Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Clinical Trial Imaging Sales Value, 2020-2031
  • 6.9.2 India Clinical Trial Imaging Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Clinical Trial Imaging Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 ICON
  • 7.1.1 ICON Profile
  • 7.1.2 ICON Main Business
  • 7.1.3 ICON Clinical Trial Imaging Products, Services and Solutions
  • 7.1.4 ICON Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.1.5 ICON Recent Developments
• 7.2 ERT
  • 7.2.1 ERT Profile
  • 7.2.2 ERT Main Business
  • 7.2.3 ERT Clinical Trial Imaging Products, Services and Solutions
  • 7.2.4 ERT Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.2.5 ERT Recent Developments
• 7.3 McLaren
  • 7.3.1 McLaren Profile
  • 7.3.2 McLaren Main Business
  • 7.3.3 McLaren Clinical Trial Imaging Products, Services and Solutions
  • 7.3.4 McLaren Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.3.5 McLaren Recent Developments
• 7.4 Bioclinica
  • 7.4.1 Bioclinica Profile
  • 7.4.2 Bioclinica Main Business
  • 7.4.3 Bioclinica Clinical Trial Imaging Products, Services and Solutions
  • 7.4.4 Bioclinica Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Bioclinica Recent Developments
• 7.5 Parexel
  • 7.5.1 Parexel Profile
  • 7.5.2 Parexel Main Business
  • 7.5.3 Parexel Clinical Trial Imaging Products, Services and Solutions
  • 7.5.4 Parexel Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Parexel Recent Developments
• 7.6 BioTelemetry
  • 7.6.1 BioTelemetry Profile
  • 7.6.2 BioTelemetry Main Business
  • 7.6.3 BioTelemetry Clinical Trial Imaging Products, Services and Solutions
  • 7.6.4 BioTelemetry Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.6.5 BioTelemetry Recent Developments
• 7.7 ProScan Imaging
  • 7.7.1 ProScan Imaging Profile
  • 7.7.2 ProScan Imaging Main Business
  • 7.7.3 ProScan Imaging Clinical Trial Imaging Products, Services and Solutions
  • 7.7.4 ProScan Imaging Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.7.5 ProScan Imaging Recent Developments
• 7.8 Imaging Endpoints
  • 7.8.1 Imaging Endpoints Profile
  • 7.8.2 Imaging Endpoints Main Business
  • 7.8.3 Imaging Endpoints Clinical Trial Imaging Products, Services and Solutions
  • 7.8.4 Imaging Endpoints Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Imaging Endpoints Recent Developments
• 7.9 Radiant Sage
  • 7.9.1 Radiant Sage Profile
  • 7.9.2 Radiant Sage Main Business
  • 7.9.3 Radiant Sage Clinical Trial Imaging Products, Services and Solutions
  • 7.9.4 Radiant Sage Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Radiant Sage Recent Developments
• 7.10 Micron, Inc.
  • 7.10.1 Micron, Inc. Profile
  • 7.10.2 Micron, Inc. Main Business
  • 7.10.3 Micron, Inc. Clinical Trial Imaging Products, Services and Solutions
  • 7.10.4 Micron, Inc. Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.10.5 Micron, Inc. Recent Developments
• 7.11 Intrinsic Imaging
  • 7.11.1 Intrinsic Imaging Profile
  • 7.11.2 Intrinsic Imaging Main Business
  • 7.11.3 Intrinsic Imaging Clinical Trial Imaging Products, Services and Solutions
  • 7.11.4 Intrinsic Imaging Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.11.5 Intrinsic Imaging Recent Developments
• 7.12 Median Technologies
  • 7.12.1 Median Technologies Profile
  • 7.12.2 Median Technologies Main Business
  • 7.12.3 Median Technologies Clinical Trial Imaging Products, Services and Solutions
  • 7.12.4 Median Technologies Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Median Technologies Recent Developments
• 7.13 Cardiovascular Imaging Technologies
  • 7.13.1 Cardiovascular Imaging Technologies Profile
  • 7.13.2 Cardiovascular Imaging Technologies Main Business
  • 7.13.3 Cardiovascular Imaging Technologies Clinical Trial Imaging Products, Services and Solutions
  • 7.13.4 Cardiovascular Imaging Technologies Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Cardiovascular Imaging Technologies Recent Developments
• 7.14 Banook Medical
  • 7.14.1 Banook Medical Profile
  • 7.14.2 Banook Medical Main Business
  • 7.14.3 Banook Medical Clinical Trial Imaging Products, Services and Solutions
  • 7.14.4 Banook Medical Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.14.5 Banook Medical Recent Developments
• 7.15 IXICO
  • 7.15.1 IXICO Profile
  • 7.15.2 IXICO Main Business
  • 7.15.3 IXICO Clinical Trial Imaging Products, Services and Solutions
  • 7.15.4 IXICO Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.15.5 IXICO Recent Developments
• 7.16 Tigermed
  • 7.16.1 Tigermed Profile
  • 7.16.2 Tigermed Main Business
  • 7.16.3 Tigermed Clinical Trial Imaging Products, Services and Solutions
  • 7.16.4 Tigermed Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.16.5 Tigermed Recent Developments
• 7.17 Runda Medical
  • 7.17.1 Runda Medical Profile
  • 7.17.2 Runda Medical Main Business
  • 7.17.3 Runda Medical Clinical Trial Imaging Products, Services and Solutions
  • 7.17.4 Runda Medical Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.17.5 Runda Medical Recent Developments
• 7.18 Konica Minolta
  • 7.18.1 Konica Minolta Profile
  • 7.18.2 Konica Minolta Main Business
  • 7.18.3 Konica Minolta Clinical Trial Imaging Products, Services and Solutions
  • 7.18.4 Konica Minolta Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.18.5 Konica Minolta Recent Developments
• 7.19 Keosys
  • 7.19.1 Keosys Profile
  • 7.19.2 Keosys Main Business
  • 7.19.3 Keosys Clinical Trial Imaging Products, Services and Solutions
  • 7.19.4 Keosys Clinical Trial Imaging Revenue (US$ Million) & (2020-2025)
  • 7.19.5 Keosys Recent Developments

8 Industry Chain Analysis

• 8.1 Clinical Trial Imaging Industrial Chain
• 8.2 Clinical Trial Imaging Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Clinical Trial Imaging Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Clinical Trial Imaging Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer